Company intelligence / Profile preview

Biosynexus Incorporated

Gaithersburg, Maryland, United Statescience.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Biosynexus developed pagibaximab, a monoclonal antibody for preventing staphylococcal sepsis in neonates, which completed Phase I/II trials showing safety and opsonic activity. Lysostaphin was tested as an intranasal cream for eradicating nasal colonization by S. aureus and entered early clinical studies. The company also worked on nisin as a topical antibacterial agent. Some programs have been discontinued or are pending further development due to strategic shifts or acquisition[1][2][3].

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodiesEnzymesPeptides
Industry: Biotech

Drug pipeline

1 asset

pagibaximab

Partnerships

GSK Biologicals ($120M deal)AMBI/Nutrition21 licensing deals

Beyond the preview

Go deeper on Biosynexus Incorporated.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biosynexus Incorporated.

Explore the full profile